Effect of oligosaccharide chain length, exposed terminal group, and hapten loading on the antibody response of human adults and infants to vaccines consisting of Haemophilus influenzae type b capsular antigen unterminally coupled to the diphtheria protein CRM197
- PMID: 2784464
Effect of oligosaccharide chain length, exposed terminal group, and hapten loading on the antibody response of human adults and infants to vaccines consisting of Haemophilus influenzae type b capsular antigen unterminally coupled to the diphtheria protein CRM197
Abstract
Vaccines consisting of oligosaccharide (OS) derived from Haemophilus influenzae type b capsular polysaccharide and conjugated to carrier proteins had been shown capable of eliciting memory-type capsular polysaccharide of H. influenza type b antibody responses in human infants, but the structural variables governing immunogenicity were not defined. Here a series of conjugates were made with the diphtheria protein CRM197 and with uniterminally coupled OS haptens that varied in chain length, exposed terminal residue, or multiplicity of loading as defined by ribose/protein ratio. Adults were given a single injection, 1-yr-old infants were given a two-injection sequence, and capsular polysaccharide of H. influenzae type b antibody responses were assessed by radioantigen binding. Vaccines C-4r, C-6r, and C-12r, in which ribitol-ended OS of mean length 4, 6, or 12 repeat units were coupled at low hapten loading, were about equally immunogenic (geometric means 2 to 5 micrograms/ml in infants, 5 to 9 micrograms/ml in adults). Vaccine C7p was made with a higher loading of OS having mean length 7 repeat units and having mainly phosphate monoester at the exposed termini Vaccine C-7R was made from a portion of C-7p by enzymatic removal of most of the terminal phosphates. Compared to the C-4r, C-6r, and C-12r series, vaccines C-7p and C-7R induced geometric means about 10-fold higher in adults and 20-fold higher in infants. Thus OS chain length (in the range studied) and exposed terminus are less critical variables in this system than the extent of hapten loading.
Similar articles
-
Vaccines consisting of periodate-cleaved oligosaccharides from the capsule of Haemophilus influenzae type b coupled to a protein carrier: structural and temporal requirements for priming in the human infant.J Immunol. 1986 Aug 15;137(4):1181-6. J Immunol. 1986. PMID: 3016088
-
Response of 7- to 15-month-old infants to sequential immunization with Haemophilus influenzae type b-CRM197 conjugate and polysaccharide vaccines.Am J Dis Child. 1991 Aug;145(8):898-900. doi: 10.1001/archpedi.1991.02160080076024. Am J Dis Child. 1991. PMID: 1858727 Clinical Trial.
-
In vitro induction of a Haemophilus influenzae type b polysaccharide-specific antibody response in human peripheral blood lymphocytes of individuals recently vaccinated with an oligosaccharide-protein conjugate.J Immunol. 1991 Dec 15;147(12):4192-9. J Immunol. 1991. PMID: 1753096
-
Background and indications for Haemophilus influenzae type b vaccines consisting of capsular antigen coupled to protein carriers.Contrib Microbiol Immunol. 1989;10:115-24. Contrib Microbiol Immunol. 1989. PMID: 2684504 Review. No abstract available.
-
Immunologic considerations for the development of conjugate vaccines.Contrib Microbiol Immunol. 1989;10:11-7. Contrib Microbiol Immunol. 1989. PMID: 2510971 Review. No abstract available.
Cited by
-
Conjugate vaccines: practice and theory.Springer Semin Immunopathol. 1993;15(2-3):217-26. doi: 10.1007/BF00201102. Springer Semin Immunopathol. 1993. PMID: 8256199 Review. No abstract available.
-
Poly(gamma-D-glutamic acid) protein conjugates induce IgG antibodies in mice to the capsule of Bacillus anthracis: a potential addition to the anthrax vaccine.Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8945-50. doi: 10.1073/pnas.1633512100. Epub 2003 Jul 11. Proc Natl Acad Sci U S A. 2003. PMID: 12857944 Free PMC article.
-
A Multidisciplinary Structural Approach to the Identification of the Haemophilus influenzae Type b Capsular Polysaccharide Protective Epitope.ACS Cent Sci. 2024 Feb 22;10(5):978-987. doi: 10.1021/acscentsci.3c01515. eCollection 2024 May 22. ACS Cent Sci. 2024. PMID: 38799664 Free PMC article.
-
Effects of chain length on the immunogenicity in rabbits of group B Streptococcus type III oligosaccharide-tetanus toxoid conjugates.J Clin Invest. 1992 Jan;89(1):203-9. doi: 10.1172/JCI115564. J Clin Invest. 1992. PMID: 1729272 Free PMC article.
-
Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel.Infect Immun. 2001 Mar;69(3):1351-7. doi: 10.1128/IAI.69.3.1351-1357.2001. Infect Immun. 2001. PMID: 11179298 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical